Drug intelligence / Profile preview

Wenfei Dingchuan Granules

Development stage: Unknown
Lead developer: Shandong Kangzhonghong
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

Wenfei Dingchuan Granules is a Traditional Chinese Medicine (TCM) candidate developed by Shandong Kangzhonghong Pharmaceutical Technology Development for the treatment of stable chronic obstructive pulmonary disease (COPD). It is specifically indicated for patients presenting with the TCM syndrome of lung-kidney qi deficiency, phlegm, and blood stasis obstructing the lung. The formulation is currently being evaluated in a Phase II randomized, double-blind, placebo-controlled, dose-exploration multicenter trial in China to assess its efficacy in improving lung function and respiratory symptoms.

Other names: 温肺定喘颗粒

Beyond the preview

Go deeper on Wenfei Dingchuan Granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wenfei Dingchuan Granules.

Explore the full profile